NORTHBROOK, Ill., May 19, 2011 (GLOBE NEWSWIRE) -- Nanosphere, Inc. (Nasdaq:NSPH), a leader in the development and commercialization of advanced molecular diagnostics systems, announced today that it will release early stage research data on potential cancer biomarkers requiring high sensitivity in an abstract for the annual meeting of the American Society of Clinical Oncology (ASCO) to be held in Chicago from June 3 to 7, 2011.
The early data suggests that three of Nanosphere's ultra-sensitive protein assays demonstrate potential clinical relevance in bladder, kidney and prostate cancers. The assays were developed and run using the Verisens™ high-throughput research platform.
The abstract can be accessed at
This research data complements data presented in April at the American Association for Clinical Chemistry's (AACC) Oak Ridge Conference, and in October 2010 at the ASCO-NCI-EORTC Annual Meeting on Molecular Markers in Cancer.
About Verisens™ and Verisens™ HT protein biomarker assays (RUO)
Verisens™ and Verisens™ HT comprise an in-vitro diagnostic assay for the high-sensitivity detection and quantification of protein and autoantibody biomarkers. Nanosphere is engaged in cancer research and validation for protein biomarkers that require high sensitivity, independently and with commercial collaborations.
In addition to cancer biomarkers, Nanosphere also provides a research-use-only cardiotoxicity assay for assessment of cancer therapeutics. The assay is based on an extremely sensitive human troponin assay. There is also a similar assay for rat troponin useful in pre-clinical studies.
For additional information regarding ultra-sensitive protein biomarkers and commercial collaborations, please contact Nanosphere at firstname.lastname@example.org.
RESEARCH USE NOTIFICATION
Nanosphere, Inc. is required by the U.S. Food and Drug Administration (FDA) to certify in writing that its customers, who purchase or who are supplied with products labeled "For Research Use Only," acknowledge and understand that such products are not for use in diagnostic or therapeutic procedures. Tests performed with in vitro products intended for "Research Use Only" are tests used in a preclinical or nonclinical setting. While research tests may be performed using either clinical or nonclinical materials, research use devices have no intended clinical use and the testing performed is not designed to provide data addressing or demonstrating safety and effectiveness. We advise our customers to monitor the use of these products, to ensure that they are used for research purposes only. Please contact Nanosphere if you have questions.
About Nanosphere, Inc.
Nanosphere develops, manufactures and markets an advanced molecular diagnostics platform, the Verigene® System, for direct genomic and ultra-sensitive protein detection. This easy to use and cost effective platform enables simple, low cost and highly sensitive genomic and protein testing on a single platform. Nanosphere is based in Northbrook, IL.
The Nanosphere, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=4344
CONTACT: Nanosphere, Inc.: Winton Gibbons (847) 400-9029 email@example.com Public and Investor Relations: The Torrenzano Group Ed Orgon (212) 681-1700 firstname.lastname@example.org